Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BURGUNDY: Zifibancimig in Neovascular Age-related Macular Degeneration
NCT04567303Phase 2Completed
- Sponsor
- Roche
- Start
- Oct 2020
- Primary completion
- Aug 2026
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of zifibancimig in neovascular age-related macular degeneration (NVAMD), sponsored by Roche. Started Oct 2020; status: completed.
02
Drugs
zifibancimig
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04567303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04567303.